Video
Noninvasive biomarker tests diagnose urothelial cancer in patients with hematuria
Author(s):
“What was very impressive from the study was by sequentially using Cxbladder Triage, Detect, and Resolve, we could not only segregate those who had cancer versus not, but also those who had low-risk tumors versus high-risk tumors,” says Jay Raman, MD, FACS.
Video Player is loading.
In this video, Jay Raman, MD, FACS,discusses the findings and takeaways of the study, “The diagnostic performance of Cxbladder Resolve, alone and in combination with other Cxbladder tests, in the identification and priority evaluation of patients at risk for urothelial carcinoma,” published in the Journal of Urology. Raman is a professor and chair of urology at Penn State Health Milton S. Hershey Medical Center, Penn State University, Pennsylvania.
Related Videos
Expert discusses the NMIBC trials landscape
John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
Joy Maulik, CRNP, on the importance of genetic testing in prostate cancer
5 key trial insights from AUA 2025
Experts discuss expanding use of vibegron for OAB
John Michael DiBianco, MD, on silicone vs polyurethane stents for patients with kidney stones
Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
Khurshid Ghani, MD, on trial of stent omission following ureteroscopy
Karyn S. Eilber, MD, shares her reaction to genitourinary syndrome of menopause guidelines
Expert discusses the relationship between RCTs and real-world efficacy of prostate cancer treatments
Related Content
